Camoteskimab

N/A

Report date: 2026/05/22 20:01:29

Base Information

Drug NameCamoteskimab
Drug Alias NameMEDI-2338AEVI-007CERC-007AVTX-007
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionInterleukin 18 inhibitors
TargetsInterleukin 18
Therapy Area/IndicationsEczemaDermatitisSkin Diseases +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[12] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesMedimmune Llc
China Registration ClassN/A

Develop Information

Active CompaniesApollo Therapeutics LtdAevi Genomic MedicineApollo Therapeutics Group Ltd +[4] 
Inactive CompaniesMedimmune Llc
Active IndicationsEczemaDermatitisSkin Diseases +[5] 
Inactive IndicationsPulmonary Disease, Chronic ObstructiveStill's Disease, Adult-Onset

Other Information

ATC CodeN/A
Related LinksN/A